Inhomogeneous Magnetoelectric Effect on Defect in Multiferroic Material: Symmetry Prediction

Inhomogeneous magnetoelectric effect in magnetization distribution heterogeneities (0-degree domain walls) appeared on crystal lattice defect of the multiferroic material has been investigated. Magnetic symmetry based predictions of kind of electrical polarization distribution in their volumes were used. It was found that magnetization distribution heterogeneity with any symmetry produces electrical polarization. Results were systemized in scope of micromagnetic structure chirality. It was shown that all 0-degree domain walls with time-noninvariant chirality have identical type of spatial distribution of the magnetization and polarization.Comment: submitted to IOP Conference Series: Materials Science and Engineerin

FREQUENCY OF INFLAMMATORY DESEASES OF UROGENITAL REGION IN MEN WITH CHRONIC TRICHOMONIASIS INFECTION AND PATHOSPERMIA

The article presents results of the examination of 39 males with chronic trichomoniasis. Revealed a high frequency of inflammatory diseases of urogenital region: in 72 % of cases was detected chronic prostatitis, in 5 % of cases — epididymitis, in 2,5 % of cases — vesiculitis. In 62 % of men with chronic trichomoniasis was detected patospermia. This results evidence suggests a possible participation of Trichomonas vaginalis in the development inflammatory diseases of urogenital region and disorder of reproductive function of men

UROGENITAL TRACT MICROFLORA IN SEXUAL PARTNERS WITH CHRONIC GENITOURINARY TRICHOMONIASIS

Trichomonas infection is a scientific and clinical problem in dermatology, urology, obstetrics and gynecology. This infection in men and women is often causes to urethritis, cystitis, prostatitis, post-abortion infection, premature labor and other diseases. This literature review has shown that in spite of a lot of numbers of scientific data concerning the impact of trichomoniasis to urogenital bioceonosis of both men and women, there is no enough data about influence of trichomoniasis to urinary microecology in sexual partners. Meanwhile, this question is in the field of scientific and applied interest and need to be studied

SPERMATOGENIC TESTICULAR FUNCTION IN MEN WITH CHRONIC UROGENITAL MONOTRICHOMONIASIS AND PATHOSPERMIA

We did not observed significant differences in levels of inhibin B and follicle-stimulating hormone in serum samples of men with chronic urogenital trichomoniasis and different spermogram. It confirmed that spermatogenic testicular function in these men is preserved

Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

Funding Information: This work was supported by the following companies since the start of EORP and for the period of the ESC Heart Failure III study: Abbott Vascular Int. (2018\u20132021), Amgen Cardiovascular (2016\u20132018), AstraZeneca AB (2017\u20132020), Bayer AG (2016\u20132018), Boehringer Ingelheim (2016\u20132019), Bristol Myers Squibb (2017\u20132019), Daichii Sankyo Europe GmbH (2017\u20132020), Edwards Lifesciences (2016\u20132019), Novartis Pharma AG (2018\u20132020), Servier (2015\u20132021), and Vifor (2019\u20132021). Publisher Copyright: © 2024 European Society of Cardiology.Aims: We analysed baseline characteristics and guideline-directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry. Methods and results: Between 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62–79], 36% women) or outpatient visit for HF (61%, age 66 [58–75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC-affiliated countries. With AHF, 97% were hospitalized, 2.2% received intravenous treatment in the emergency department, and 0.9% received intravenous treatment in an outpatient clinic. AHF was seen by most by a general cardiologist (51%) and outpatient HF most by a HF specialist (48%). A majority had been hospitalized for HF before, but 26% of AHF and 6.1% of outpatient HF had de novo HF. Baseline use, initiation and discontinuation of GDMT varied according to AHF versus outpatient HF, de novo versus pre-existing HF, and by ejection fraction. After the AHF event or outpatient HF visit, use of any renin–angiotensin system inhibitor, angiotensin receptor–neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist and loop diuretics was 89%, 29%, 92%, 78%, and 85% in HFrEF; 89%, 9.7%, 90%, 64%, and 81% in HFmrEF; and 77%, 3.1%, 80%, 48%, and 80% in HFpEF. Conclusion: Use and initiation of GDMT was high in cardiology centres in Europe, compared to previous reports from cohorts and registries including more primary care and general medicine and regions more local or outside of Europe and ESC-affiliated countries.publishersversionepub_ahead_of_prin